Hikma enters Spanish generic injectables market

Hikma is in an expansion mode. The company has established Hikma Spain. 

This marks Hikma’s official entry into Spain, which has a generic injectable market size of approximately $860 million, per IQVIA 2023 generic injectable, hospital sector data.

In the year to date, Hikma has received 36 product approvals and launched 25 products in Spain. These span several therapeutic areas including cardiovascular, oncology, central nervous system and antiinfectives. 

[Read more: Hikma intros Kloxxado]

The entry into the Spanish market strengthens the group’s established and growing presence in Europe, the company said. This includes manufacturing plants in Portugal, Italy and Germany, which supply injectable products to North America, Europe, and Middle East and North Africa. 

Hikma is already supporting the Spanish hospitals by providing key oncological molecules that are currently in shortage, the company noted.

Bill Larkins, president of Hikma Injectables said, “The expansion into Spain is another important milestone in our global strategy to grow and strengthen our Injectables’ commercial presence in Europe and around the world. We have an agile supply chain, a growing product portfolio and regional manufacturing capabilities, which will enable us to supply Spanish hospitals and their patients with the high-quality injectable medicines they need. We look forward to building our presence here.” 

[Read more: Hikma intros Kloxxado]

Carola Warleta, commercial head of Hikma Spain said, “We are launching the Spanish affiliate at a time when the hospital sector is in need of a reliable and quality supplier. I am confident in our ability to work hand in hand with healthcare professionals and authorities to provide high-quality and affordable medicines to patients in Spain.”